suvorexant
suvorexant: 8 clinical trials tracked.
suvorexant evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about suvorexant, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (8)
Suvorexant: Targeting Orexin to Augment Exposure Therapy in Veterans With PTSD and Insomnia
Primary endpoint: Change from Baseline in PTSD Symptom Severity as Assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 4, Week 8, and 6 Months
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Primary endpoint: enrollment
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder
Primary endpoint: Change from Baseline in Total Sleep Time at Week 8
A Double-masked, Randomized, Phase II Study to Compare the Effectiveness of 20mg Oral Suvorexant (SUV) Versus Placebo (1:1) in Participants With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)
Primary endpoint: Change in Insomnia Severity Index (ISI) score from baseline to Day 14.
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Primary endpoint: Participant Reported Insomnia Symptoms Evaluated Using the Insomnia Severity Index (ISI)
Improvement of Restorative Sleep and Post-surgical Insomnia Following Suvorexant Administration
Primary endpoint: Total Sleep Time on Day 0 (TST)
Orexin's Role in The Neurobiology of Substance Use Disorder
Primary endpoint: fMRI - cue reactivity
Sleep Trial to Prevent Alzheimer's Disease
Primary endpoint: Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217 in participants treated with 20 mg suvorexant compared to placebo